e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Lung cancer: prognostic factors and features of oncogene-driven tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung cancer patients harbouring epidermal growth factor receptor mutation
Catarina Carvalho de Oliveira Dias (Matosinhos, Portugal), Catarina Dias, David Araujo, Adriana Magalhaes, Henrique Queiroga, Venceslau Espanhol, Jose Machado, Conceiçao Moura, Agostinho Marques, Gabriela Fernandes
Source:
International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session:
Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type:
Thematic Poster Session
Number:
4253
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Catarina Carvalho de Oliveira Dias (Matosinhos, Portugal), Catarina Dias, David Araujo, Adriana Magalhaes, Henrique Queiroga, Venceslau Espanhol, Jose Machado, Conceiçao Moura, Agostinho Marques, Gabriela Fernandes. Lung cancer patients harbouring epidermal growth factor receptor mutation. Eur Respir J 2015; 46: Suppl. 59, 4253
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
The roles of Ki-67, p53, transforming growth factor- and lysyl oxidase in the metastasis of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Rhesus CE expression is an independent prognostic factor in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Feasibility of bronchoscopy obtained tissue for tumor diagnosis and testing epidermal growth factor receptor (EGFR) mutational status
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Polymorphism of
HLA-G
gene promotor in patients with non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
CD33
+
CD14
-
CD11b
+
CD66b
+
CD15
+
VEGFR-1
hi
myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept